Related Experiment Video
Updated: Sep 10, 2025

Catheter-based Endovascular Angioplasty for Fibrosing Mediastinitis-associated Pulmonary Vein Stenosis
Published on: August 26, 2025
Unmasking pulmonary veno-occlusive disease after vasodilator therapy in limited cutaneous systemic sclerosis
Nanditha Sidda1, Rama Bhat2, Praveen Tirlangi3
1General Medicine, Kasturba Medical College Manipal, Manipal, Karnataka, India.
Abstract:
Pulmonary veno-occlusive disease (PVOD) is a rare but severe cause of pulmonary hypertension that is often misdiagnosed as pulmonary arterial hypertension (PAH). It is crucial to differentiate PVOD from PAH, as the initiation of pulmonary vasodilators in PVOD cases can lead to worsening symptoms. PVOD is characterised by widespread occlusion of the pulmonary veins due to fibrosis and intimal proliferation. Although systemic sclerosis (SSc) is a well-established risk factor for PAH, its association with PVOD is rare and often overlooked. This case involves a woman in her early 40s with limited cutaneous SSc who developed progressive dyspnoea. Initially diagnosed with PAH, her condition worsened after starting pulmonary vasodilators. This case highlights the importance of considering PVOD in SSc patients and the need for careful diagnostic and therapeutic strategies.
Related Concept Videos
Antihypertensive Drugs: Vasodilators
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Varicose Veins II: Diagnostic Studies and Interprofessional Care
Peripheral Artery Disease IV: Nursing Management

